MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ESPR made $87,309,000 in revenue. -$31,333,000 in net income. Net profit margin of -35.89%.

Income Overview

Revenue
$87,309,000
Net Income
-$31,333,000
Net Profit Margin
-35.89%
EPS
-$0.16
Unit: Dollar
Revenue Breakdown
    • Collaboration Revenue
    • Product

Unit: Dollar
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Total revenues
87,309,000 -64,995,000 103,424,000
Cost of goods sold
41,289,000 -31,538,000 17,853,000
Research and development
14,131,000 -12,557,000 12,190,000
Selling, general and administrative
41,848,000 -42,996,000 39,456,500
Total operating expenses
97,268,000 -87,091,000 69,499,500
(loss) income from operations
-9,959,000 7,095,000 -22,096,000 33,924,500
Interest expense
22,051,000 20,486,000 19,431,000 15,223,000
Loss on extinguishment of debt
0 0 --561,000
Other income, net
677,000 666,000 1,072,000 1,992,000
Net loss
-31,333,000 -12,725,000 -40,455,000 19,852,000
Comprehensive loss
-31,333,000 -12,725,000 -40,455,000 19,852,000
Net loss per common share - basic (in dollars per share)
-0.16 -0.06 -0.21 0.1
Net loss per common share - diluted (in dollars per share)
-0.16 -0.06 -0.21 0.1
Weighted-average shares outstanding - basic (in shares)
200,736,136 197,546,239 196,127,948 -98,271,395
Weighted-average shares outstanding - diluted (in shares)
200,736,136 197,546,239 196,127,948 -98,271,395
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$31,333,000 Net loss-$31,333,000 Other income, net$677,000 Collaboration Revenue$46,650,000 Product$40,659,000 Interest expense$22,051,000 (loss) income fromoperations-$9,959,000 Total revenues$87,309,000 Total operatingexpenses$97,268,000 Selling, general andadministrative$41,848,000 Research and development$14,131,000 Cost of goods sold$41,289,000

Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics, Inc. (ESPR)